Why Adaptimmune Therapeutics Crushed the Market Today

Adaptimmune Therapeutics (NASDAQ: ADAP), a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. Following the release of detailed phase 2 clinical trial results for a promising cancer treatment, the company's shares rose by nearly 4.5% on the day.

In advance of a June industry congress, Adaptimmune unveiled the results of its SPEARHEAD-1 study. This was undertaken to gauge the efficacy of its afamitresgene autoleucel, or afami-cel, to treat synovial sarcoma (cancer of soft tissue such as muscles or ligaments) and myxoid/round cell liposarcoma (MRCLS; a cancer of the cells that store fat).

Image source: Getty Images.

Continue reading

Source Fool.com